Clinical Trial: HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07232875) titled 'HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer' on Nov. 14.

Brief Summary: This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

Intervention: DRUG: HRS-4642 + AG

HRS-4642 + AG

DRUG: HRS-4642 placebo + AG

HRS-4642 placebo + ...